The aim of this article was to review the current literature on capsular contractures, focusing in particular on the epidemiology, risk factors, cause, and treatment modalities, to provide the plastic surgeon with an up-todate review of the current available evidence. Methods: A literature search was undertaken of the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases. The search strategy was conducted using three groups of key words, with the first relating to the organ involved (breast), the second relating to the surgical procedure performed and related technical issues, and the third relating to the surgical complications. Potentially relevant articles were identified by means of the title and the abstract, and full articles were obtained and assessed in detail. Results: Only a few studies have included large enough sample sizes, were conducted in a prospective manner, were adequately randomized, and achieved adequate follow-up periods to obtain a true measure of rates of capsular contraction occurrence. Recent advances in molecular biology, microbiology, immunology, and basic pathology have outlined some of the mechanisms that underlie this phenomenon. Revision surgery remains the only effective treatment option available but is limited by its high associated risk of recurrences. No adequate preventative measures exist in practice, beyond the avoidance of risk factors. Conclusions: Although a great deal of progress has been made over the past few decades, the exact nature and contribution of molecular, immunologic, and microbiological factors remain unclear. It is hoped that future studies will focus on attempting to resolve some of the issues highlighted in this review. (Plast.
C apsular contracture is a complication of breast implants that presents with signs ranging from breast induration, which eventually progresses, to the development of a painful breast, with total distortion of its shape and volume. When the implant is placed, a capsule of fibrous material forms around it. The capsule is initially thin and soft, with little or no effect on the appearance of the breast; however, with time, it undergoes a progressive thickening, becomes harder, and shrinks in such a way that it may alter the breast contours and produce a range of symptoms varying from local tenderness to severe pain. This process, also known as capsular contracture, compromises the aesthetic outcome and usually requires surgical removal of prostheses. 1 In this article, the authors review the current literature relating to this complication of breast implant surgery, focusing particularly on occurrence rates, risk factors, cause, and treatment modalities to provide the plastic surgeon with an up-to-date review of the current available evidence.
MATERIALS AND METHODS
A literature search was undertaken for all studies focusing on capsular contractures following breast augmentation or reconstruction. Articles were selected from the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases in February of 2009. The search strategy was conducted using three groups of key words, with the first relating to the organ involved (breast), the second relating to the surgical procedure performed and related technical issues, and the third relating to the surgical complication. Key words used for the organ involved were breast and mammary. Key words used for the surgical procedure were enlargement, augmentation, reconstruction, mammaplasty, mastoplasty, implant, prosthesis, prostheses, expander, silicone, saline, polyurethane, textured, smooth, subglandular, submuscular, subfascial, single-lumen, doublelumen, capsulectomy, and capsulotomy. Key words used for the surgical complication were capsular, capsule, contraction, contracture, hardness, firmness, and thickness. All types of studies were included in the search strategy. No language restrictions were adopted.
Potentially relevant articles were identified by the title, and the abstracts and full articles were obtained and assessed in detail. Two authors (A.A. and G.G.) assessed them and evaluated their suitability for inclusion in the review. If no abstract was available, the decision was based on the title alone. The reference list of each article (including copies of previously published reviews on the topic) was also screened to identify further relevant reports. TrialsCentral (www.trialscentral.org) and Current Controlled Trials (www.controlled-trials.com) databases were screened for the existence of any randomized trials relating to the search criteria that were ongoing.
A specifically designed data form was used to collect all relevant information, including the parameters analyzed, the type of analysis conducted, and results obtained. Data collection and analysis was carried out independently by two researchers (A.A. and G.G.).
RESULTS

Risk Factors
Reported rates of capsular contractures vary widely, ranging from 1.3 to 30 percent of patients who receive implants. 2, 3 The longer the implants were in place, the greater the cumulative risk of developing contracture, which would suggest a direct correlation between when the implant is placed and the time to developing contractures. 2 Approximately 92 percent of contractures occur within the first 12 months following surgery. 4 A number of parameters seem to influence the occurrence of contractures, including the indications for surgery (breast reconstructions versus cosmetic augmentations), type of prosthesis used (smooth versus textured and saline versus silicone), and positioning of the implant (subglandular versus submuscular). In light of their apparent significance in the etiopathogenesis of contractures, these factors have been the subject of much scrutiny in a number of different studies.
Reconstruction versus Cosmetic Augmentation
Capsular contractures occur more frequently after breast reconstruction than after aesthetic augmentation, with reported rates of 10.4 percent of patients at a mean follow-up of 36.7 months. 5, 6 Important factors that could influence the occurrence of contractures following breast reconstruction are the preoperative or postoperative exposure to chemotherapy 5 and/or radiotherapy. [7] [8] [9] Both treatments impair the local immunologic status of the tissues, increasing the rate of subclinical infections. 10 -16 This enhances the natural fibrosis of tissues that normally occurs after the placement of a foreign body in the organism. However, the overall pathology of this complication is not fully understood, to the extent that the net contribution of these effects toward the development of contractures is unknown.
The influence of adjuvant chemotherapy on breast reconstructive surgery has been investigated extensively in the literature (Table 1) . [17] [18] [19] [20] [21] [22] All studies were conducted retrospectively and included in their analysis either immediate or delayed reconstructions and implant-based or autologous-based reconstructions (Table 1) . 22 Breast reconstructions did not delay the administration of chemotherapy 17,19 -22 other than in the case of reconstruction using the transverse rectus abdominis myocutaneous flap. In this setting, chemotherapy was delayed on average by 5 more days because of poor wound healing. 23 All studies but one 20 showed that adjuvant chemotherapy did not increase the occurrence of wound complications after reconstruction. 17, 18 Also of note is the fact that no study has yet investigated the long-term side effects of chemotherapy on tissues, including, for example, rates of capsular contracture.
Radiotherapy increases the incidence of implant and capsule ruptures, hematomas, and wound infections but, most importantly, it affects also the incidence of capsular contractures. The contracture rate is higher in all irradiated groups (Table 2) , 6 -9,24 -32 but this characteristic is not shared by chemotherapy (Table 1) . Unfortunately, most studies are retrospective in nature and analyze groups of patients who received radiotherapy at variable time points (before, during, Volume 124, Number 6 • Capsular Contractures or after reconstruction), concomitant chemotherapy, implant positioning or type, and type of contractures reported (only Baker grade 3 or 4 versus all contractures). Furthermore, some studies included small sample sizes, insufficient to adequately evaluate the occurrence of capsular contractures. 8, 26, 27 All of these factors may partly explain the wide range of reported contractures in the irradiated groups (32 to 73 percent) versus nonirradiated groups (0 to 40 percent). Despite this variability, all studies agree on the significant effect that radiotherapy has on increasing the risk of developing capsular contractures.
Sullivan et al. 33 investigated the influence of the type of reconstruction (autologous tissue versus breast implantation with smooth saline-filled prostheses placed subpectorally) and the timing of the procedure (immediate versus delayed reconstruction) on the occurrence of capsular contractures. Two-hundred fifty cancer patients were analyzed and, after 4 years of follow-up, no significant differences in the rates of contractures were noted between the immediate versus delayed reconstruction groups when autologous tissues were used (52.4 percent versus 36.4 percent; p ϭ not significant). However, a higher rate of contractures was present in the group that received immediate reconstruction when breast prostheses were used for reconstruction (40.4 percent versus 17.0 percent; odds ratio, 2.4; p ϭ 0.001).
33
Shell Characteristics
Numerous studies have demonstrated that textured surfaces produced a lower incidence of contractures when compared with smooth ones (Table 3), 34 -41 a finding further confirmed by two metanalyses. 42, 43 In the first meta-analysis, Barnsley et al. proved the protective effect of textured implants over smooth surfaces (relative risk, 0.19; 95 percent confidence interval, 0.07 to 0.52), with smooth implants showing a five-times greater risk of contracture formation. 42 In the second metaanalysis, 235 patients were analyzed, and textured implants were shown to produce fewer capsular contractures when compared with smooth implants at 1 year (relative risk, 4.2; 95 percent confidence interval, 1.6 to 11.0), 3 years (relative risk, 7.3; 95 percent confidence interval, 2.4 to 21.7), and 7 years of follow-up (relative risk, 3.0; 95 percent confidence interval, 0.9 to 10.4). 43 Only one study showed no significant differences between smooth versus textured implants for the occurrence of capsular contractures. 41 However, this trial had a Jadad score of 2, indicating a poor methodologic quality with a high degree of variance in the results.
41,44
Implant Positioning Partial or complete submuscular placement and subfascial positioning have also been investigated to elucidate their association with rates of capsular contractures. Seckel and Costas retrospectively studied 76 patients (146 breasts) who had undergone partial or total submuscular breast cosmetic augmentation. 45 No difference was observed between the total and the partial musculofascial coverage for the occurrence of capsular contractures [zero of 35 (0 percent) versus one of 41 (0.02 percent); Fisher's exact test, p ϭ not significant]. Hendricks reviewed 650 patients who had received textured silicone gel implants beneath the pectoralis major muscle, the external oblique muscle, the rectus sheath, and the serratus anterior muscle fascia. 46 In this study, no cases of Baker grade 3 or 4 capsular contractures were reported. Ventura and Marcello retrospectively analyzed 100 patients who had received primary breast enlargement with textured implants positioned in the subfascial compartment and found that only two patients (2 percent) experienced Baker grade 2 capsular contractures. 47 Finally, in a retrospective multicenter study of more than 500 patients, Gutowski et al. found that the use of subglandular positioning of the prosthesis increased the risk of capsular contractures by almost eight times. 48 There are probably a number of explanations for the reduced occurrence of capsular contractures following submuscular and subfascial placement compared with the subglandular position. Generally speaking, the more tissue that covers the implants and minimizes the contact with glandular tissues, the smaller the risk of capsular contracture. All muscles involved (i.e., the pectoralis major, external oblique, rectus sheath, and serratus anterior muscle fascia) create a contiguous structure that completely separates the implant from the breast tissue. The pectoralis major usually guarantees a thick layer of tissue over the implants, which may delay the clinical detection of contractures. Furthermore, capsules under the muscles usually receive a spontaneous and continuous "massaging" effect, derived from surrounding muscular contractions, which favors an anatomical and physiologic organization of the collagen fibers within the capsule. 46 Finally, implants placed over the muscle come into direct OR, odds ratio; RCT, randomized controlled trial; NS, not significant. *All trials were conducted on patients undergoing aesthetic primary breast augmentations. Most of the high-quality studies (Jadad score ϭ 3) showed significantly different occurrences of capsular contractures between smooth vs. textured surfaces, except for the study of Tarpila et al. 39 †The studies of Malata et al. 37 and Collis et al. 40 presented results of the randomized trial of Coleman et al. 35 after 3 and 10 years of follow-up, respectively.
Volume 124, Number 6 • Capsular Contractures contact with breast ducts (which are well known to harbor bacteria), whereas implants placed below the muscle are sheltered from this exposure. The human breast is not a sterile anatomical structure. The endogenous flora derived from the nipple ducts are essentially the same as those found in the normal skin because the multiple ducts form passages from the skin surface to deep within the breast tissue. Coagulase-negative staphylococci, diphtheroids, lactobacilli, Bacillus species, ␤-hemolytic streptococci, anaerobic microorganisms, and Propionibacterium acnes have been isolated from within these ducts. 49 Thus, implants placed on top of the muscle come into direct contact with breast ducts, well known for harboring bacteria, whereas implants placed below the muscle are afforded some protection from contamination.
Other Factors
Other factors are reported in the literature, but most of them are anecdotal in nature and lack a strong enough evidence base to inform medical practice. However, those associated with a high occurrence of capsular contractures were contamination with bacteria, [12] [13] [14] [15] [16] the absence of intraluminal steroids or antibiotics during surgery, 50 silicone-filled prostheses, [51] [52] [53] silicone breast implant ruptures, 54 connective tissue diseases, 55 and postoperative hematomas. 56 Protective factors, in contrast, included the low-bleed elastomer shell, 57 saline-filled prostheses, 51, 52, 56, 58 limited handling of the implants during surgery, and irrigation with triple-antibiotic solutions during surgery. 59, 60 The use of polyurethane-coated implants seemed to have a protective effect in two retrospective series, both of which had an adequately long follow-up. However, an experimental study that compared polyurethane foam-covered implants with otherwise identical smooth silicone gel implants failed to confirm the findings of the retrospective studies. [61] [62] [63] Furthermore, the evidence for irrigation with steroids around the breast capsule is limited to experimental studies and needs to be confirmed in clinical trials.
50,64
Etiopathogenesis
After breast surgery involving the positions of an implant, capsules of tightly woven collagen fibers commonly form around the foreign body to wall it off. However, in some patients, the interaction between inflammatory cells, extracellular matrix, and fibroblasts leads to an abnormal response. [65] [66] [67] Specialized fibroblasts with an increased ability to contract are found within the capsules around static implants and skin expanders. They are also found in wound granulation tissue, which is typically found to be responsible for wound contractions. 68, 69 Within the process of normal wound healing, these fibroblasts disappear after wound closure, whereas in hypertrophic scars or keloid scars they persist, leading to an excessive response. The presence of these fibroblasts in capsules around implants could leadwith the presence of concomitant risk factors-to an overreactive response. 70 -73 Breast implant capsules are also partially composed of bone marrowderived cells that, given their potential to become myofibroblasts, may further contribute to the formation of the capsular contractures. 74 Microbiological and immunologic hypotheses have been postulated to explain the pathophysiology of capsular contracture. The microbiological theory proposes that agents present in the periprosthetic space could be responsible for subclinical infections and chronic inflammation. Their pathogenicity is not significant enough to give a symptomatic implant infection, but it may produce a mild chronic inflammation, predisposing to the formation capsular contracture. This theory is supported by studies that found a bacterial biofilm contamination around the implant. 12, 13, 75 Schreml et al. swabbed 45 patients suffering from unilateral capsular fibrosis following augmentation mammaplasty with silicone implants and found no colonization for Baker grade 1 to 2 contractures versus 67.7 percent colonization of Baker grade 3 or 4 contractures. 16 The evidence against the microbiological theory includes the following: (1) specific investigations failed to consistently identify microbiological agents in the periprosthetic space when capsular contracture was detected; (2) an insignificant number of patients among those that developed capsular contractures gave a history of early postoperative periprosthetic infections 6, 30 ; and (3) perioperative antibiotics did not reduce the occurrence of contractures. 76 According to the immunologic theory, systemic and local factors are responsible for a chronic inflammatory process. 77 A progressive fibrotic tissue forms in the periprosthetic space, and numerous serum indexes of fibrosis (e.g., hyaluronan, the aminoterminal propeptide of procollagen type III, the matrix metalloproteinases, and tissue inhibitor of metalloproteinases) were all elevated in patients manifesting contractures following breast augmentation. 78, 79 These indexes also correlated with the degree of contracture. 80 However, this theory failed to demonstrate a corPlastic and Reconstructive Surgery • December 2009 relation between any susceptibility conferred by the major histocompatibility complex type and contractures. Furthermore, no studies showed any significant association between local and systemic variations in cytokine concentrations within patients who developed contractures.
Treatment
Various classifications have been proposed to score the severity of capsular contractures (Table  4) , 4, 81 but the most widely used remains the Baker grading system. 4 This scale is a peculiar mixture of symptoms and signs that is quite simple to apply. In fact, the question "does the breast feel as soft as a normal breast?" differentiates between grades 1 or 2 versus grades 3 or 4. After that, the surgeon uses his or her judgment to decide between grades 1 and 2 or between grades 3 and 4. 35 Attempts have been made to develop more objective assessments of contractures (e.g., by use of some types of tonometers or caliper devices [82] [83] [84] ), but these methods have not become widely accepted.
According to the Baker classification, only the highest degrees of contractures (grades 3 and 4) require surgical treatment. The available options are removal of the implant followed by open capsulotomy, or capsulectomy. Closed capsulotomy 28, 85 consists of the manual compression of the breast in an attempt to break the capsular scar tissue. This procedure has long since been abandoned because of an increased risk of hematoma, shell rupture with silicone leakage, and scar rupture leading to implant "pseudoherniation." It remains a bone of contention as to whether capsulectomy is appropriate in this context. In 1992, the American Society of Plastic and Reconstructive Surgeons recommended that fibrous capsules should be left in place when silicone implants were removed; otherwise, thickening capsule produced breast distortion or rupture of the implant, complicated by extrusion of silicone contents. 86 The statement recognizes that capsulectomy requires more extensive surgical dissection, thereby increasing the associated risks. Authors advocating the use of capsulectomy defended their position on the basis of the fact that it prevents calcium deposition because the capsule is removed. Calcium accumulates within capsules left in the body, with subsequent interference with routine mammography. [87] [88] [89] Furthermore, clinical reports have shown the persistence of capsules and their ability to produce contractures long after silicone implants have been removed. 87 Experimental studies using silicone material found cellular reactions and calcium deposition in capsules after the implant had been removed, 90, 91 but not in salinefilled prostheses. In the case of saline-filled prostheses, the capsules progressively contract over the course of a few weeks after removal of the implant, fold during a period of 1 to 2 months, and eventually disappear completely after 1 year. 92 After breast implant removal and capsulectomy, breast reconstruction may be achieved by autologous tissue transfer (flaps) or reimplantation with a second implant. Flaps are especially useful when multiple capsulectomies and implant exchanges have already been attempted. Different flap types have been described for the salvage of breast reconstruction. 29, 93, 94 Results obtained at long-term follow-up have demonstrated an aesthetically satisfactory appearance of the breasts. 93 When reimplantation is considered, it is very important to take into account the position of previous implants. For subglandular implants, the capsulectomy is followed by reimplantation in the submuscular position. 46 This approach ensures adequate tissue coverage, implant support and, crucially, the avoidance of direct contact between the new implants and the heavily inflamed submammary tissue. Indeed, the recurrence of capsular contractures is extremely high when implants are reinserted in the same position after capsulectomy. Open capsulotomy requires circumferential and longitudinal incisions over the capsule to cut through the thick scar envelope that deforms the implant. 67, 95 This technique leaves the capsule on the tissues but reduces the tightness and the deformation. It is not as radical a treatment as capsulectomy. Therefore, it should be reserved for Although capsular contracture is a multifactorial process, a common factor in the successful treatment of this complication is the reduction of the inflammatory process. Leukotrienes have been shown to be involved in the activation and up-regulation mechanisms that lead to capsular contracture. 98 It has been suggested that leukotriene antagonists are potentially useful in dampening inflammation, leading to a dense collagen membrane around the prosthesis and thus preventing contracture. An in vivo study demonstrated a statistically significant reduction in fibrosis and capsule formation in a group of rats treated with zafirlukast compared with controls. 99 In a pilot study, Scuderi et al. reported that the use of zafirlukast reduced the mammary compliance in patients with already existing capsular contractures. They reportedly confirmed their findings in a second prospective study in which zafirlukast-treated patients were compared with controls. 100, 101 However, a careful evaluation of the methodology adopted for the conduction of the studies, the statistical analysis used, and the results presented suggested that the evidence provided to support the drug efficacy was tenuous at the best. Furthermore, hepatic failure after leukotriene antagonists is a rare but serious complication, with high levels of associated morbidity. 102 The authors offered serial postoperative liver function tests to monitor the patients' hepatic function, 102 but the associated risk may outweigh the benefits as a treatment modality for a contracted capsule. Le Louarn et al. recently published data on a locally active antiinflammatory patch that is suggested to downgrade the capsular contracture from Baker grade 2 or 3 to Baker grade 1 if the patch is applied no later than 3 months after the onset of capsular contracture. 103 However, future studies are needed to evaluate the clinical effectiveness of these agents in relation to their role in the prevention and cure of this complication.
CONCLUSIONS
Although it is apparent from the articles studied in this review that a great deal of progress has been made over the past few decades toward elucidating the etiopathogenesis of capsular contractures, the exact nature and contribution of molecular, immunologic, and microbiological factors remain unclear. Only a few studies have included large enough sample sizes, were conducted in a prospective manner, were adequately randomized, and achieved adequate follow-up periods to obtain a true measure of the rates of capsular contracture occurrence. Therefore, there is a scant and often inconclusive body of evidence relating to this complication. For example, the contribution of chemotherapy to the occurrence of capsular contractures warrants more thorough investigation. Likewise, the possibility of preventing this complication by use of experimental drugs needs to be looked at more closely. Revision surgery remains the only effective treatment option available to us at this time but is limited by its high associated risk of recurrences and complications (hematoma or pneumothorax) when the implant is originally placed in the submuscular position. It is hoped that future studies will focus on attempting to resolve some of the issues highlighted in this review.
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